Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia

Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia

Bibliographic Details
Main Authors:	Michael L. Martini, Sean N. Neifert, J Mocco, Fedor Panov, Winona Tse, Ruth H. Walker, Jian Jin, Fiona Gupta
Format:	Article
Language:	English
Published:	Korean Movement Disorder Society 2019-09-01
Series:	Journal of Movement Disorders
Online Access:	http://www.e-jmd.org/upload/jmd-19029.pdf

Similar Items

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
by: Alejandro Martinez-Carrasco, et al.
Published: (2023-08-01)

Berberis vulgaris alleviates Levodopa-induced dyskinesia in male mice
by: Mokarian Faezeh, et al.
Published: (2018-12-01)

Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia
by: Heiman, Myriam, et al.
Published: (2014)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
by: Destany K. Kwon, et al.
Published: (2022-11-01)

SELECTIVE ACTIVATION OF STRIATAL INDIRECT PATHWAY SUPPRESSES LEVODOPA-INDUCED DYSKINESIAS
by: Ivan Castela, et al.
Published: (2023-10-01)

Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias
by: Iván Castela, et al.
Published: (2023-01-01)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
by: Jinyoung Youn, et al.
Published: (2022-05-01)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
by: Noriko Nishikawa, et al.
Published: (2022-09-01)

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
by: Michał Hutny, et al.
Published: (2021-09-01)

Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming
by: Takashi Nakamura, et al.
Published: (2023-06-01)

Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study
by: Bruno Lopes Santos-Lobato, et al.
Published: (2023-05-01)

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)

Brain-Region Specific Metabolic Abnormalities in Parkinson’s Disease and Levodopa-Induced Dyskinesia
by: Changwei Yang, et al.
Published: (2020-03-01)

Potential efficacy of nanocurcumin on levodopa-induced dyskinesia in a rat parkinsonian model
by: Pegah Ashrafi, et al.
Published: (2022-11-01)

Radiomics and Hybrid Models Based on Machine Learning to Predict Levodopa-Induced Dyskinesia of Parkinson’s Disease in the First 6 Years of Levodopa Treatment
by: Yang Luo, et al.
Published: (2023-07-01)

Slow wave activity across sleep-night could predict levodopa-induced dyskinesia
by: Ninfa Amato, et al.
Published: (2023-09-01)

Investigation of <i>PRKN</i> Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
by: Ana Gabrielle Bispo, et al.
Published: (2023-08-01)

Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
by: Svetlana A. Ivanova, et al.
Published: (2018-08-01)

Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
by: Han Soo Yoo, et al.
Published: (2022-07-01)

Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson’s disease
by: Jeongrak Park, et al.
Published: (2024-01-01)

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
by: Foltynie, T, et al.
Published: (2009)

Dose–response relationship of levodopa with dyskinesia in Parkinson's disease: A systematic review and meta-analysis
by: Taozhi He, et al.
Published: (2024-03-01)

Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
by: Xingyue Cao, et al.
Published: (2024-03-01)

Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes
by: Luca Pagliaroli, et al.
Published: (2021-06-01)

Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation
by: Fanshi Zhang, et al.
Published: (2023-10-01)

Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia
by: Mark M. Lin, et al.
Published: (2019-01-01)

Downregulation of striatal CaV1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age
by: Margaret E. Caulfield, et al.
Published: (2023-06-01)

Dyskinesia-hyperpyrexia syndrome in Parkinson's disease triggered by overdose of levodopa — a case report and literature review
by: Xiangnan Du, et al.
Published: (2024-01-01)

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism
by: Masatoshi Ogawa, et al.
Published: (2019-12-01)

Treatment of Levodopa-induced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial
by: Amir Hassan Habibi, et al.
Published: (2018-10-01)

Levodopa-Induced Dyskinesia Is Associated with Increased Thyrotropin Releasing Hormone in the Dorsal Striatum of Hemi-Parkinsonian Rats
by: Cantuti-Castelvetri, Ippolita, et al.
Published: (2011)

Discovery of levodopa-induced dyskinesia-associated genes using genomic studies in patients and Drosophila behavioral analyses
by: Woongchang Yoon, et al.
Published: (2022-08-01)

Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions
by: Lazzaro di Biase, et al.
Published: (2023-06-01)

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
by: József Attila Szász, et al.
Published: (2021-06-01)

Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson’s disease
by: Joung Eun Kim, et al.
Published: (2023-11-01)

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia
by: Mitchell J. Bartlett, et al.
Published: (2020-12-01)

Levodopa-induced pseudopheochromocytoma
by: Joana Bernardino Cardoso, et al.
Published: (2023-05-01)

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
by: Manuela eMellone, et al.
Published: (2015-07-01)

Lessons from the CONSCIOUS-1 Study
by: Alexander J. Schupper, et al.
Published: (2020-09-01)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)